No Data
12 Health Care Stocks Moving In Friday's Pre-Market Session
For The FY24, At Constant Exchange Rates, Molecular Partners Reiterates Its Guidance For Total Expenses Of CHF 65–70 Million. ~CHF 7 Million Of This Will Be Non-Cash Effective Costs For Share-Based Payments, Pension Accounting And Depreciation. This...
Molecular Partners Radio-DARPin Therapy Candidate MP0712 Supported By In Vivo Data Presented At The European Association Of Nuclear Medicine Congress; First-In-Human Start And Initial Clinical Data Expected In 2025
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
Molecular Partners Stock Climbs 6% on Expanded Radiopharmaceuticals Deal
Molecular Partners, Orano Med Report Positive Preclinical Data on MP0712
No Data
No Data